vs

Side-by-side financial comparison of Arcellx, Inc. (ACLX) and ALT5 Sigma Corp (ALTS). Click either name above to swap in a different company.

Arcellx, Inc. is the larger business by last-quarter revenue ($8.1M vs $5.4M, roughly 1.5× ALT5 Sigma Corp). Arcellx, Inc. runs the higher net margin — -766.0% vs -7100.2%, a 6334.2% gap on every dollar of revenue. On growth, ALT5 Sigma Corp posted the faster year-over-year revenue change (12.5% vs -79.3%). ALT5 Sigma Corp produced more free cash flow last quarter ($-7.2M vs $-63.9M).

Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.

ALT5 Sigma Corp is a fintech firm focused on digital asset infrastructure and trading solutions. It operates regulated digital asset trading platforms for retail and institutional clients, primarily serving markets across North America, Europe, and the Asia-Pacific region. Its core offerings include spot and derivatives trading, digital asset custody, and secure settlement services.

ACLX vs ALTS — Head-to-Head

Bigger by revenue
ACLX
ACLX
1.5× larger
ACLX
$8.1M
$5.4M
ALTS
Growing faster (revenue YoY)
ALTS
ALTS
+91.8% gap
ALTS
12.5%
-79.3%
ACLX
Higher net margin
ACLX
ACLX
6334.2% more per $
ACLX
-766.0%
-7100.2%
ALTS
More free cash flow
ALTS
ALTS
$56.8M more FCF
ALTS
$-7.2M
$-63.9M
ACLX

Income Statement — Q1 FY2025 vs Q4 FY2025

Metric
ACLX
ACLX
ALTS
ALTS
Revenue
$8.1M
$5.4M
Net Profit
$-62.3M
$-381.5M
Gross Margin
40.9%
Operating Margin
-847.6%
-38.1%
Net Margin
-766.0%
-7100.2%
Revenue YoY
-79.3%
12.5%
Net Profit YoY
-765.1%
-7249.1%
EPS (diluted)
$-1.13
$-5.53

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACLX
ACLX
ALTS
ALTS
Q4 25
$5.4M
Q3 25
$7.6M
Q2 25
$6.4M
Q1 25
$8.1M
$5.5M
Q4 24
$15.3M
$4.8M
Q3 24
$26.0M
$4.9M
Q2 24
$27.4M
$2.2M
Q1 24
$39.3M
$0
Net Profit
ACLX
ACLX
ALTS
ALTS
Q4 25
$-381.5M
Q3 25
$49.0M
Q2 25
$-9.1M
Q1 25
$-62.3M
$-2.9M
Q4 24
$-47.1M
$-5.2M
Q3 24
$-25.9M
$-822.0K
Q2 24
$-27.2M
$589.0K
Q1 24
$-7.2M
$-2.1M
Gross Margin
ACLX
ACLX
ALTS
ALTS
Q4 25
40.9%
Q3 25
34.6%
Q2 25
43.5%
Q1 25
47.0%
Q4 24
45.8%
Q3 24
47.8%
Q2 24
50.6%
Q1 24
Operating Margin
ACLX
ACLX
ALTS
ALTS
Q4 25
-38.1%
Q3 25
-218.3%
Q2 25
-32.8%
Q1 25
-847.6%
-39.4%
Q4 24
-348.2%
-40.8%
Q3 24
-129.1%
-14.8%
Q2 24
-127.8%
-112.2%
Q1 24
-40.3%
Net Margin
ACLX
ACLX
ALTS
ALTS
Q4 25
-7100.2%
Q3 25
646.4%
Q2 25
-142.9%
Q1 25
-766.0%
-51.9%
Q4 24
-308.4%
-108.7%
Q3 24
-99.4%
-16.6%
Q2 24
-99.3%
27.2%
Q1 24
-18.3%
EPS (diluted)
ACLX
ACLX
ALTS
ALTS
Q4 25
$-5.53
Q3 25
$0.29
Q2 25
$-0.49
Q1 25
$-1.13
$-0.18
Q4 24
$-0.87
$-0.35
Q3 24
$-0.48
$-0.06
Q2 24
$-0.51
$0.07
Q1 24
$-0.14
$-0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACLX
ACLX
ALTS
ALTS
Cash + ST InvestmentsLiquidity on hand
$543.3M
$6.2M
Total DebtLower is stronger
$563.0K
Stockholders' EquityBook value
$416.9M
$1.2B
Total Assets
$648.1M
$1.2B
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACLX
ACLX
ALTS
ALTS
Q4 25
$6.2M
Q3 25
$7.3M
Q2 25
$9.6M
Q1 25
$543.3M
$10.8M
Q4 24
$587.4M
$7.2M
Q3 24
$574.3M
$8.7M
Q2 24
$516.7M
$5.8M
Q1 24
$573.9M
$61.0K
Total Debt
ACLX
ACLX
ALTS
ALTS
Q4 25
$563.0K
Q3 25
Q2 25
Q1 25
Q4 24
$563.0K
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ACLX
ACLX
ALTS
ALTS
Q4 25
$1.2B
Q3 25
$1.6B
Q2 25
$26.1M
Q1 25
$416.9M
$21.8M
Q4 24
$454.8M
$12.4M
Q3 24
$483.0M
$20.2M
Q2 24
$487.2M
$22.9M
Q1 24
$496.6M
$3.8M
Total Assets
ACLX
ACLX
ALTS
ALTS
Q4 25
$1.2B
Q3 25
$1.6B
Q2 25
$94.7M
Q1 25
$648.1M
$78.0M
Q4 24
$711.3M
$75.7M
Q3 24
$764.9M
$74.9M
Q2 24
$734.3M
$75.4M
Q1 24
$779.7M
$18.6M
Debt / Equity
ACLX
ACLX
ALTS
ALTS
Q4 25
0.00×
Q3 25
Q2 25
Q1 25
Q4 24
0.05×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACLX
ACLX
ALTS
ALTS
Operating Cash FlowLast quarter
$-63.1M
$-7.2M
Free Cash FlowOCF − Capex
$-63.9M
$-7.2M
FCF MarginFCF / Revenue
-786.4%
-133.4%
Capex IntensityCapex / Revenue
9.6%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-122.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACLX
ACLX
ALTS
ALTS
Q4 25
$-7.2M
Q3 25
$-8.7M
Q2 25
$-5.2M
Q1 25
$-63.1M
$-1.5M
Q4 24
$-46.0M
$1.8M
Q3 24
$30.7M
$4.2M
Q2 24
$-36.2M
$80.0K
Q1 24
$-31.9M
$-544.0K
Free Cash Flow
ACLX
ACLX
ALTS
ALTS
Q4 25
$-7.2M
Q3 25
Q2 25
Q1 25
$-63.9M
Q4 24
$-47.5M
Q3 24
$28.4M
Q2 24
$-39.5M
Q1 24
$-38.3M
FCF Margin
ACLX
ACLX
ALTS
ALTS
Q4 25
-133.4%
Q3 25
Q2 25
Q1 25
-786.4%
Q4 24
-311.3%
Q3 24
109.2%
Q2 24
-144.1%
Q1 24
-97.7%
Capex Intensity
ACLX
ACLX
ALTS
ALTS
Q4 25
0.2%
Q3 25
Q2 25
Q1 25
9.6%
Q4 24
9.8%
Q3 24
8.8%
Q2 24
11.7%
Q1 24
16.4%
Cash Conversion
ACLX
ACLX
ALTS
ALTS
Q4 25
Q3 25
-0.18×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.14×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons